MedTrace Logo

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

NCT01117233 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-01-18

No results posted yet for this study

Summary

The purpose is to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers

Conditions

  • Healthy

Interventions

DRUG

PF-04427429

single intravenous infusion of 10 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 30 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 100 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 300 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 1000 mg PF-04427429 or placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01117233 on ClinicalTrials.gov